Playtex board grows
This article was originally published in The Rose Sheet
Executive Summary
Playtex Products elects Maureen Tart-Bezer to its board of directors, firm announces May 2. "An experienced financial and management executive," Tart-Bezer has served as the executive VP and CFO of Virgin Mobile USA, executive VP and general manager of the American Express Company's consumer group, and as a senior financial officer at AT&T, Playtex says. She currently serves as director to The Great Atlantic & Pacific Tea Company. Tart-Bezer is "a welcome addition to our Board of Directors. We expect that her strong financial background and significant management experience will benefit Playtex as we evolve from being a turnaround situation to being a growth-oriented company," CEO Neil DeFeo states. In April, Playtex acquired Hawaiian Tropic sun care (1"The Rose Sheet" April 23, 2007, In Brief)...
You may also be interested in...
Playtex buys Hawaiian Tropic
Playtex Products has acquired Tiki Hut Holding Company, the owners of Hawaiian Tropic for $83 mil., according to an April 19 release. Playtex projects that sales from its skin-care segment will increase to more than $340 mil. annually as a result of the deal. In 2006, net sales of Hawaiian Tropic products in the tanning, sun protection, baby and kids, sunless tanning, after-sun, burn relief and lip protection segments exceeded $110 mil., Playtex says, adding that Hawaiian Tropic previously was "the largest privately-held sun-care manufacturer in the world." The firm expects to derive annual synergies from the deal of $11 mil. The business will be fully synergized by FY 2009...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.